To include your compound in the COVID-19 Resource Center, submit it here.

Acorda sinks after FDA refuses Inbrija NDA

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $6.25 (24%) to $19.45 on Tuesday after FDA issued a refusal to file letter to an NDA for Inbrija

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE